Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats

Hepatology

Volumn 47, Issue 4, 2008, Pages 1264-1276

  Trebicka, Jonel ^a   Leifeld, Ludger ^a   Hennenberg, Martin ^a   Biecker, Erwin ^a   Eckhardt, Andreas ^a   Fischer, Nicolas ^a   Pröbsting, Andrea Schulze ^a   Clemens, Christoph ^a   Lammert, Frank ^a   Sauerbruch, Tilman ^a   Heller, Jörg ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRATE; NITRIC OXIDE; NITRITE; PALOSURAN; RECEPTOR BLOCKING AGENT; RECEPTOR PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SODIUM; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II; UROTENSIN II RECEPTOR; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DIURESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; MEDIATOR; MESENTERIC ARTERY; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SODIUM EXCRETION; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HEMODYNAMICS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MESENTERIC ARTERIES; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PORTAL VEIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; UREA; UROTENSINS;

EID: 42249103587     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22170     Document Type: Article

References (46)

1. Murray J, Dawson A, Sherlock S. Circulatory changes in chronic liver. Am J Med 1958;24:358-367.
2. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999;19:359-382.
3. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-156.
4. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-778.
5. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999;19:411-426.
6. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-854.
7. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. HEPATOLOGY 2007;45:495-506.
8. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286.
9. Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 2000;36:S163-S166.
10. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-1274.
11. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001;132:1625-1629.
12. Gardiner SM, March JE, Kemp PA, Maguire JJ, Kuc RE, Davenport AP, et al. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 2006;147:612-621.
13. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 2006;29:375-387.
14. Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006;148:884-901.
15. Song W, Abdel-Razik AE, Lu W, Ao Z, Johns DG, et al. Urotensin II and renal function in the rat. Kidney Int 2006;69:1360-1368.
16. Balment RJ, Song W, Ashton N. Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. Ann N Y Acad Sci 2005;1040:66-73.
17. Matsushita M, Shichiri M, Fukai N, Ozawa N, Yoshimoto T, Takasu N, et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 2003;144:1825-1831.
18. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002;37:767-772.
19. Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, et al. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007;27:1232-1239.
20. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl) -urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther 2004;311:204-212.
21. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krahenbuhl S, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006;80:246-256.
22. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006;316:1115-1121.
23. Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, et al. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003;33:1006-1012.
24. Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999;154:1711-1720.
25. Porstmann T, Kiessig ST. Enzyme immunoassay techniques: an overview. J Immunol Methods 1992;150:5-21.
26. Avrameas S. Amplification systems in immunoenzymatic techniques. J Immunol Methods 1992;150:23-32.
27. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. HEPATOLOGY 2007;46:242-253.
28. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A, et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000;87:999-1005.
29. Ibarra-Alvarado C, Galle J, Melichar VO, Mameghani A, Schmidt HH. Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol Pharmacol 2002;61:312-319.
30. Mulsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 2001;103:2188-2194.
31. Fukata Y, Kimura K, Oshiro N, Saya H, Matsuura Y, Kaibuchi K. Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. J Cell Biol 1998;141:409-418.
32. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-1305.
33. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
34. Seyde WC, Longnecker DE. Anesthetic influences on regional hemodynamics in normal and hemorrhaged rats. Anesthesiology 1984;61:686-698.
35. Van de Casteele M, Sagesser H, Zimmermann H, Reichen J. Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Ther 2001;90:35-43.
36. Hakkinen JP, Miller MW, Smith AH, Knight DR. Measurement of organ blood flow with coloured microspheres in the rat. Cardiovasc Res 1995;29:74-79.
37. Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am J Physiol 1989;257:G52-G57.
38. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88:1102-1104.
39. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000;130:1865-1870.
40. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-24271.
41. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005;97:1232-1235.
42. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-824.
43. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003;284:R1-R12.
44. Mookerjee RP, Wiesenthal A, Icking A, Hodges SJ, Davies NA, Schilling K, et al. Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis. Gastroenterology 2007;132:2533-2541.
45. Pateron D, Tazi KA, Sogni P, Heller J, Chagneau C, Poirel O, et al. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000;119:196-200.
46. Lang F, Tschernko E, Schulze E, Ottl I, Ritter M, Volkl H, et al. Hepatorenal reflex regulating kidney function. HEPATOLOGY 1991;14:590-594.